<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02211846</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-202</org_study_id>
    <secondary_id>2014-000340-15</secondary_id>
    <nct_id>NCT02211846</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder</brief_title>
  <official_title>A Multicentre, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS Tablets in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetics as well as the safety and&#xD;
      tolerability of mirabegron OCAS tablets after single-dose administration at different dose&#xD;
      levels in children and adolescents with NDO or OAB.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2014</start_date>
  <completion_date type="Actual">September 21, 2015</completion_date>
  <primary_completion_date type="Actual">September 21, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: Cmax</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: tmax</measure>
    <time_frame>Day 1-7</time_frame>
    <description>The time after dosing when Cmax occurs (tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: AUCinf</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Area under the curve extrapolated until time is infinity (AUCinf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameter of mirabegron: t1/2</measure>
    <time_frame>Day 1-7</time_frame>
    <description>Apparent terminal elimination half-life (t1/2 )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by adverse events, clinical laboratory evaluations, vital signs (including 24-h Holter for heart rate), electrocardiogram (ECG), physical examination, post-void residual volume (PVR)</measure>
    <time_frame>up to Day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Neurogenic Detrusor Overactivity</condition>
  <condition>Overactive Bladder</condition>
  <condition>Pharmacokinetics of Mirabegron</condition>
  <arm_group>
    <arm_group_label>Mirabegron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered under fed and fasted conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>oral</description>
    <arm_group_label>Mirabegron</arm_group_label>
    <other_name>Myrbetriq</other_name>
    <other_name>Betmiga</other_name>
    <other_name>Betanis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a documented diagnosis of:&#xD;
&#xD;
               -  Neurogenic detrusor overactivity (NDO), or&#xD;
&#xD;
               -  Idiopathic overactive bladder (OAB) according to International Children's&#xD;
                  Continence Society (ICCS) criteria.&#xD;
&#xD;
          -  Subject's weight/height:&#xD;
&#xD;
               -  Subject should have a body weight of ≥ 20.0 kg (all cohorts).&#xD;
&#xD;
               -  For NDO: subject is not suffering from malnutrition and is not severely&#xD;
                  overweight, in the opinion of the Investigator.&#xD;
&#xD;
               -  For OAB: subject's weight and height are within the normal percentiles (3rd to&#xD;
                  97th percentile) according to Centers for Disease Control and Prevention (CDC)&#xD;
                  growth charts.&#xD;
&#xD;
          -  Subject is able to swallow the study medication in accordance with the protocol.&#xD;
&#xD;
          -  Female subject must either:&#xD;
&#xD;
               -  Be of non-childbearing potential:&#xD;
&#xD;
               -  Clearly pre-menarchal or in the judgment of the Investigator is pre-menarchal&#xD;
&#xD;
               -  Documented surgically sterile.&#xD;
&#xD;
               -  Or, if of childbearing potential: Agree not to try to become pregnant during the&#xD;
                  study and for 28 days after the final study drug administration,&#xD;
&#xD;
               -  And have a negative urine pregnancy test pre-dose Day 1,&#xD;
&#xD;
               -  And, if heterosexually active agree to consistently use two forms of highly&#xD;
                  effective form of birth control starting at screening and throughout the study&#xD;
                  period and for 28 days after the final study drug administration.&#xD;
&#xD;
          -  Female subjects must agree not to breastfeed starting at screening and throughout the&#xD;
             study period, and for 28 days after the last study drug administration.&#xD;
&#xD;
          -  Female subject must not donate ova starting at screening and throughout the study&#xD;
             period, and for 28 days after the final study drug administration.&#xD;
&#xD;
          -  Male subject and their female spouse/partner who are of childbearing potential must be&#xD;
             using a highly effective form of contraception consisting of two forms of birth&#xD;
             control (one of which must be a barrier method) starting at screening and continuing&#xD;
             throughout the study period, and for 28 days after the final study drug&#xD;
             administration.&#xD;
&#xD;
          -  Male subject must not donate sperm starting at Screening and throughout the study&#xD;
             period, and for 90 days after study drug administration.&#xD;
&#xD;
          -  Subject and subject's parent(s)/legal guardian agree that the subject will not&#xD;
             participate in another interventional study while on treatment.&#xD;
&#xD;
          -  Subject and subject's parent(s)/legal guardian are willing and able to comply with the&#xD;
             study requirements and with the concomitant medication restrictions&#xD;
&#xD;
        Exclusion Criteria At Screening:&#xD;
&#xD;
          -  Subject is pregnant.&#xD;
&#xD;
          -  Subject has a known history of QTc prolongation or risk of QT prolongation (e.g.&#xD;
             hypokalemia, family history of Long QT Syndrome).&#xD;
&#xD;
          -  Subject has an abnormal (mean) pulse rate according to the ranges specified below: age&#xD;
             5 to less than 8 years: &lt; 60 bpm or &gt; 110 bpm; age 8 to less than 12 years: &lt; 55 bpm&#xD;
             or &gt; 100 bpm; age 12 to less than 18 years: &lt; 50 bpm or &gt; 100 bpm.&#xD;
&#xD;
          -  Subject has any clinically significant ECG abnormality.&#xD;
&#xD;
          -  Subject has mean systolic blood pressure greater than the 95th percentile according to&#xD;
             age and height and/or greater than 140 mmHg [National Institute of Health, 2005].&#xD;
&#xD;
          -  Subject has any clinically significant or unstable medical condition or disorder&#xD;
             which, in the opinion of the Investigator, precludes the subject from participating in&#xD;
             the study.&#xD;
&#xD;
          -  Subject has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater&#xD;
             than or equal to 2 times the upper limit of normal (ULN) or total bilirubin greater&#xD;
             than or equal to 1.5 times the ULN.&#xD;
&#xD;
          -  Subject has severe renal impairment (estimated glomerular filtration rate (MDRD) &lt; 30&#xD;
             mL/min).&#xD;
&#xD;
          -  Subject has any other clinically significant out of range results of urinalysis,&#xD;
             biochemistry or hematology.&#xD;
&#xD;
          -  Subject has a history or current diagnosis of any malignancy.&#xD;
&#xD;
          -  Subject has known or suspected hypersensitivity to mirabegron, other ß3-agonists, any&#xD;
             of the excipients used in the OCAS tablet formulation or previous severe&#xD;
             hypersensitivity to any drug.&#xD;
&#xD;
          -  Subject meets any of the contra-indications or precautions for use of mirabegron as&#xD;
             mentioned in the Investigator's Brochure (IB).&#xD;
&#xD;
          -  Subject has used mirabegron in the past (last intake less than 12 days before planned&#xD;
             reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject requires ongoing treatment with any of the following prohibited medications:&#xD;
&#xD;
               -  Any anticholinergic/antimuscarinic drugs within 5 half-lives prior to planned&#xD;
                  reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any drugs that are sensitive CYP2D6 substrates with a narrow therapeutic index&#xD;
                  (such as thioridazine, flecainide, propafenone, imipramine, desipramine) and&#xD;
                  sensitive P-gp substrates (such as digoxin, dabigatran) within 5 half-lives prior&#xD;
                  to the planned reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any moderate or strong cytochrome CYP3A4/5 or P-gp inhibitors or inducers&#xD;
                  including natural and herbal remedies (such as itraconazole, rifampicin,&#xD;
                  phenytoin, carbamazepine, St. John's Wort, grapefruit, Seville orange) within 5&#xD;
                  half-lives prior to the planned reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject has a positive urinary drug screen test for drugs of abuse.&#xD;
&#xD;
          -  Subject donated blood or blood products within 3 months prior to planned Day 1.&#xD;
&#xD;
          -  Subject has participated in another clinical trial and/or has taken an investigational&#xD;
             drug within 30 days (or 5 half-lives of the investigational drug, whichever is longer)&#xD;
             prior to the planned reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject's parent(s)/legal guardian is an employee of the Astellas Group, any Contract&#xD;
             Research Organization (CRO) involved, or the Investigator site executing the study.&#xD;
&#xD;
          -  Subject has current, untreated constipation (or fecal impaction for NDO patients). If&#xD;
             the constipation is being consistently treated for the last month, the subject can be&#xD;
             included.&#xD;
&#xD;
          -  Subject has been administered intradetrusor botulinum toxin injections; except if&#xD;
             given &gt; 4 months prior to screening and symptoms reappeared comparable to those before&#xD;
             botulinum toxin injections.&#xD;
&#xD;
        Exclusion Criteria At day 1:&#xD;
&#xD;
          -  Subject has a positive urinary drug screen test for drugs of abuse.&#xD;
&#xD;
          -  Subject has a positive alcohol breath test.&#xD;
&#xD;
          -  Subject has used mirabegron in the past (last intake less than 24 days before planned&#xD;
             reference day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject requires ongoing treatment with any of the following prohibited medications:&#xD;
&#xD;
               -  Any anticholinergics/antimuscarinics within 5 half-lives prior to intake of the&#xD;
                  reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any drugs that are sensitive CYP2D6 substrates with a narrow therapeutic index&#xD;
                  (such as thioridazine, flecainide, propafenone, imipramine, desipramine) and&#xD;
                  sensitive P-gp substrates (such as digoxin, dabigatran) within 5 half-lives prior&#xD;
                  to the reference day (Day -4 to Day -1).&#xD;
&#xD;
               -  Any moderate or strong cytochrome CYP3A4/5 or P-gp inhibitors or inducers&#xD;
                  including natural and herbal remedies (such as itraconazole, rifampicin,&#xD;
                  phenytoin, carbamazepine, St. John's Wort) within 5 half-lives prior to reference&#xD;
                  day (Day -4 to Day -1).&#xD;
&#xD;
          -  Subject donated blood or blood products within 3 months prior to Day 1.&#xD;
&#xD;
          -  Subject (female subjects of childbearing potential) has a positive urinary pregnancy&#xD;
             test.&#xD;
&#xD;
          -  Subject has a current symptomatic urinary tract infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Research Physician</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site BE32009 Univ.Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32003 Gent University Hospital</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32004 AZ Groeninge, Campus Vercruyss</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site BE32011 U.Z. Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45003 Aalborg Sygehus Nord</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45001 Uni Hosp of Aarhus, Skejby</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45005 Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45004 Børnelægen i Køge</name>
      <address>
        <city>Koege</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site DK45002 Kolding Sygehus</name>
      <address>
        <city>Kolding</city>
        <zip>6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site NO47001 Haukeland Sykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48003 Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48001 Pomnik-Centrum Zdrowia Dziecka</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site RS38010 Mother and Child Health Care</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/patientStudySearch.aspx?RID=;;;178-CL-202</url>
    <description>Link to results on the Astellas Clinical Study Results website.</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Mirabegron</keyword>
  <keyword>Neurogenic detrusor overactivity (NDO)</keyword>
  <keyword>Overactive bladder (OAB)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under &quot;Sponsor Specific Details for Astellas.&quot;</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02211846
org study id: 178-CL-202
secondary id: 2014-000340-15
nct id: NCT02211846
lead sponsor: 
collaborator: 
has dmc: No
The purpose of this study is to evaluate the pharmacokinetics as well as the safety and
      tolerability of mirabegron OCAS tablets after single-dose administration at different dose
      levels in children and adolescents with NDO or OAB.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Basic Science
masking: None (Open Label)
measure: Pharmacokinetic parameter of mirabegron: Cmax
time frame: Day 1-7
description: Maximum concentration (Cmax)
measure: Pharmacokinetic parameter of mirabegron: tmax
time frame: Day 1-7
description: The time after dosing when Cmax occurs (tmax)
measure: Pharmacokinetic parameter of mirabegron: AUCinf
time frame: Day 1-7
description: Area under the curve extrapolated until time is infinity (AUCinf)
measure: Pharmacokinetic parameter of mirabegron: t1/2
time frame: Day 1-7
description: Apparent terminal elimination half-life (t1/2 )
measure: Safety as assessed by adverse events, clinical laboratory evaluations, vital signs (including 24-h Holter for heart rate), electrocardiogram (ECG), physical examination, post-void residual volume (PVR)
time frame: up to Day 7
arm group label: Mirabegron
arm group type: Experimental
description: Administered under fed and fasted conditions
intervention type: Drug
intervention name: Mirabegron
description: oral
arm group label: Mirabegron
other name: Myrbetriq
other name: Betmiga
other name: Betanis
criteria: 
gender: All
minimum age: 5 Years
maximum age: 17 Years
healthy volunteers: No
last name: Clinical Research Physician
role: Study Director
affiliation: Astellas Global Development
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Belgium
country: Denmark
country: Norway
country: Poland
country: Serbia
url: https://astellasclinicalstudyresults.com/patientStudySearch.aspx?RID=;;;178-CL-202
description: Link to results on the Astellas Clinical Study Results website.
responsible party type: Sponsor
mesh term: Urinary Bladder, Overactive
mesh term: Mirabegron
sharing ipd: No
ipd description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."